ReviewBiomarker research2024
New strategies for lung cancer diagnosis and treatment: applications and advances in nanotechnology.
Review in Biomarker research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Innovative technologies and their clinical prospects for early lung cancer screening.Clinical and experimental medicine · 2025Pooled it
- Radiomics analysis of dual-layer spectral detector CT-derived iodine density maps for predicting the pathological complete response of esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy.European journal of radiology open · 2026Article
- EGFR exon 20-altered NSCLC in China: molecular heterogeneity and real-world outcomes with sunvozertinib.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Fibrin-Binding Peptide-Functionalized HBiomedicines · 2026Article
- Article
- Major Postoperative Complications and Survival After Lung Cancer Resection in Patients Aged ≥80 Years: Risk Factor Analysis.Current oncology (Toronto, Ont.) · 2026Article
- Heterogeneity of urinary system tumors: novel avenues for targeted therapy and precision medicine.Journal of advanced research · 2026Review
- Cascade-activatable small-molecule theranostic nanomicelles for photodynamic-immunotherapy of immune-cold lung tumors.Asian journal of pharmaceutical sciences · 2026Article
- The Application of Micro/Nanorobots in Cancer Therapy.Micromachines · 2026Review
- Identification of glycolysis -correlative features for predicting prognosis and investigating immune landscape in prostate cancer.BMC cancer · 2026Article
- BUB1 promotes cell stem-like properties and serves as a diagnostic biomarker for lung cancer.Scientific reports · 2026Article
- PTGDS is a potential marker for lung adenocarcinoma identified in a pancancer analysis.Scientific reports · 2026Article
- Integrating Clinical Features, Laboratory Biomarkers and Computed Tomography for the Discrimination of Non-Small Cell Lung Cancer and Benign Pulmonary Diseases: A Clinical Prediction Model.Journal of clinical laboratory analysis · 2026Article
- Operative lung cancer patients' knowledge of pulmonary rehabilitation.Frontiers in physiology · 2026Article
- Machine learning constructs a ferroptosis related signature for predicting prognosis and drug sensitivity in lung cancer.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- CDC6 as a pan-cancer immunological and prognostic biomarker and its role in suppressing melanoma malignancy.BMC cancer · 2025Article
- Comprehensive characterization of the molecular feature of acetylation in colorectal cancer using integrated single-cell and bulk RNA sequencing.Scientific reports · 2025Article
- Polymeric Nanoparticles for Targeted Lung Cancer Treatment: Review and Perspectives.Pharmaceutics · 2025Review
- CTSS and CD53: Emerging m6A methylation markers in diabetic kidney disease pathogenesis and their clinical implications.BMC nephrology · 2025Article
- Exploring the relationship between hypoxia in lung adenocarcinoma and tumor microenvironment immune cell infiltration.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Lung cancer leads in causing cancer-related mortality worldwide, continually posing a significant threat to human health. Current imaging diagnostic techniques, while offering non-invasive detection, suffer from issues such as insufficient sensitivity and the risks associated with radiation exposure. Pathological diagnosis, the gold standard for confirmation, also faces challenges like invasiveness and high costs. In treatment, surgery, radiotherapy, and chemotherapy are the main modalities, each encountering challenges related to precision, environmental adaptability, and side effects. Nanotechnology's advancement provides new solutions for the diagnosis and treatment of lung cancer, promising to enhance diagnostic accuracy and reduce side effects during treatment. This article introduces the main types of nanomaterials used in the field of lung cancer, offering a comprehensive overview of current research on the application of nanotechnology in early screening, diagnosis, treatment, and monitoring of lung cancer, and summarizing ongoing clinical research findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.